In heart failure, pirfenidone may reduce the expression of col-1 induced by TGFβ, decrease vascular permeability, and inhibit inflammation and fibrosis caused by NLRP3, thereby alleviating the development of pressure overload-induced chronic cardiac fibrosis (32, 33). This evidence concerns the gene NLRP3 and heart failure.